
Press Release – July 2023
EMM is pleased to announce its successful FDA audit review that took place earlier this month resulting in no 483 observations or letters being issued.
- July 2023: EMM-NY (USA) successfully completed an audit by the USA Food & Drug Administration base upon regulation 21CFR820, Quality System Regulation (QSR).
The regulatory and quality assurance practices carried out at EMM in compliance with the Food & Drug Administration standards are a testament to EMM’s staff who go above and beyond to work toward achieving these results. Results of this nature further instill confidence from our customers that they can rely on our expertise and knowledge within the industry. Our quality systems at both our manufacturing facilities and our New York office provide a quality compliance capability which is strong, continuously improved, and reliable for our customers, end users and EMM global operations as a whole.
